Skip to main content
ATOSSA THERAPEUTICS, INC. logo

ATOSSA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · ATOS ISIN · US04962H5063 US Manufacturing
Open in API
Filings indexed 622 across all filing types
Latest filing 2012-09-13 Capital/Financing Update
Country US United States of America
Listing US ATOS

About ATOSSA THERAPEUTICS, INC.

https://atossatherapeutics.com/

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative medicines for areas of significant unmet medical need, with a primary focus on oncology. The company is dedicated to addressing the full continuum of breast cancer care. Its lead program is centered on (Z)-endoxifen, a proprietary and potent selective estrogen receptor modulator (SERM). Atossa is advancing (Z)-endoxifen through clinical development for multiple breast cancer indications, including metastatic disease, aiming to provide a therapeutic with a potentially improved efficacy and tolerability profile.

Recent filings

Filing Released Lang Actions
FORM FWP
Capital/Financing Update Classification · 95% confidence The document is titled 'FREE WRITING PROSPECTUS' and is filed pursuant to Rule 433, which relates to issuer free writing prospectuses used in securities offerings. It references a preliminary prospectus and a registration statement on Form S-1, indicating it is related to a securities offering. The content includes recent developments about a business agreement and unaudited financial data, but it is not a full financial report or earnings release. The document is relatively short (4616 characters) and serves as a supplement to a prospectus rather than a standalone financial report. Therefore, it is best classified as a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2012-09-13 English
Regulatory Filings 2012
Regulatory Filings Classification · 95% confidence The document is a letter from Atossa Genetics Inc. to the SEC requesting effectiveness of a Registration Statement on Form S-1. It is a formal correspondence related to a securities registration process, not a financial report or earnings release. The document is short (2120 characters) and serves as a regulatory communication rather than a report containing financial data or analysis. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2012-09-13 English
Capital/Financing Update 2012
Capital/Financing Update Classification · 95% confidence The document is a letter addressed to the SEC regarding a Registration Statement on Form S-1, specifically requesting acceleration of the effective date of the Registration Statement. It mentions distribution of the Preliminary Prospectus and compliance with SEC rules related to securities offerings. This is related to capital raising activities and the registration process for securities issuance. The document is not a financial report, earnings release, or management discussion, but rather an update on the capital raising process and regulatory compliance. Therefore, it fits best under Capital/Financing Update (CAP). The document length is short and it is not announcing a report publication, so it is not RPA or RNS. Confidence is high given the clear context and content.
2012-09-10 English
Regulatory Filings 2012
Regulatory Filings Classification · 95% confidence The document is a letter from Atossa Genetics Inc. to the SEC requesting effectiveness of a Registration Statement on Form S-1. It references the Form S-1 registration statement and acknowledges the inclusion of financial statements dated June 30, 2012 in the prospectus. The document is a correspondence related to a regulatory filing process, specifically the effectiveness of a registration statement, and does not contain financial statements or detailed financial data itself. The document length is short (2303 characters) and it is a formal request letter rather than a report or financial disclosure. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and correspondence with the SEC that do not fit other categories.
2012-09-07 English
FORM S-1/A
Regulatory Filings Classification · 100% confidence The document is an Amendment No. 8 to Form S-1 Registration Statement filed with the SEC, dated August 30, 2012. It is a registration statement under the Securities Act of 1933 for Atossa Genetics Inc. The text includes detailed information about the company, the securities being registered, the offering price, underwriting details, and extensive disclosures typical of an IPO registration statement. The document is not a financial report, earnings release, or management discussion but a regulatory filing to register securities for public offering. Form S-1 and its amendments are classic examples of registration statements for initial public offerings or other securities offerings. Therefore, this document fits best under the category of Regulatory Filings (RNS), as it is a regulatory filing that does not fit into other specific categories like capital/financing update or proxy solicitation. The document length (15,000 characters) and content confirm it is not a brief announcement or a report publication announcement but a full regulatory filing.
2012-08-30 English
S-1/A
Capital/Financing Update Classification · 100% confidence The document is an Amendment No. 7 to Form S-1 Registration Statement filed with the SEC, dated August 20, 2012, for Atossa Genetics Inc. It is a registration statement under the Securities Act of 1933, used for initial public offerings (IPOs) or other securities offerings. The text includes detailed information about the company, its business, risk factors, management discussion and analysis, financial condition, and the offering details. This is a regulatory filing related to capital raising and securities registration, not a financial report, earnings release, or other types of filings. The Form S-1 and its amendments are classic Capital/Financing Update filings as they relate to the registration of securities for public offering. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it is the actual filing, not just an announcement or certification, so it is not RPA or RNS.
2012-08-21 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.